How it works
A triple GIP, GLP-1, and glucagon receptor agonist combining incretin signaling, satiety, and energy expenditure.
CATALOG ITEM
Retatrutide
Certificate of analysis (COA)
- Strength
- 10 mg
- Batch number on the certificate (Batch Number)
- CS-re10-1006
- Analysis date
Identifying details were hidden for privacy. The test results are shown as they appeared in the original report. For research use only.
Retatrutide (RETA): strengths, packs and COAs
RETA is shorthand for Retatrutide. This catalog entry brings the Retatrutide research peptide's strength and pack options together under its full name, with the selected option's price and available certificate of analysis (COA).
| Labeled strength | Units per pack |
|---|---|
| 10 mg | 10 vials |
| 20 mg | 10 vials |
| 30 mg | 10 vials |
| 40 mg | 10 vials |
| 50 mg | 10 vials |
| 60 mg | 10 vials |
| 100 mg | 10 vials |
Select a strength above to see its current pack price. These are catalog specifications, not instructions for use.
Reviewing the Retatrutide COA
The certificate panel above follows the selected strength. Check the material name, strength, batch number and analysis date on the report. A certificate describes the tested sample and batch; it does not establish results for every pack or other batches.
When no certificate is available for the selected strength, the panel says so. The certificate library includes the available reports and a search by product or batch number.
What it is studied in
RETA is studied for obesity, overweight, type 2 diabetes, and metabolic fatty-liver disease.
Key benefits
Metabolism, glucose regulation, food intake, and body-composition endpoints.
What sets it apart
The triple agonist in this catalogue: GIP, GLP-1, and glucagon in one molecule.